Market Cap: $253.84M
RI
Rocket Pharmaceuticals, Inc.
RCKT
NASDAQ (NASDAQ Global Market)USD
Market Cap: $253.84M
Rocket Pharmaceuticals Leverages FDA Voucher for Strategic Growth Rocket Pharmaceuticals, a leader in the development of innovative therapies for rare genetic diseases, is taking a strategic step to e…
Avant Technologies: Pioneering Precision Medicine in Cardiovascular Health Avant Technologies Inc., a Vancouver-based company, emerges as a significant player in the burgeoning field of precision medi…
Precision Medicine and Cardiovascular Health: A New Era in Therapeutics Rocket Pharmaceuticals operates within a rapidly evolving landscape of precision medicine, a sector that is witnessing unprecede…
Rocket Pharmaceuticals Advances Gene Therapy for Rare Diseases Rocket Pharmaceuticals, a leader in the field of gene therapy, continues to make strides in the treatment of rare genetic disorders. The…
Rocket Pharmaceuticals Emphasizes Advancements in Gene Therapy Amid Market Volatility Rocket Pharmaceuticals, a leader in the field of gene therapy, continues to make strides in developing innovative…
Navigating Regulatory Challenges in Gene Therapy: uniQure's FDA Feedback on Huntington's Disease Treatment In a significant development for the biopharmaceutical industry, uniQure N.V. receives crucia…
Regulatory Milestone for Gene Therapy in Huntington’s Disease In a significant development for the field of gene therapy, uniQure N.V. receives valuable feedback from the U.S. Food and Drug Administra…
Rocket Pharmaceuticals Sees FDA Progress for Kresladi: A Milestone in Gene Therapy Development Rocket Pharmaceuticals, Inc. has achieved a significant milestone with the U.S. Food and Drug Administrat…
Rocket Pharmaceuticals Advances Gene Therapy for Rare Disease with FDA Submission Rocket Pharmaceuticals, Inc. has achieved a significant milestone in its pursuit of innovative treatments for genetic…
Rocket Pharmaceuticals Faces Scrutiny Amid Allegations of Misleading Shareholders Rocket Pharmaceuticals, Inc. finds itself under investigation by Kuehn Law, PLLC, following serious allegations of bre…
Rocket Pharmaceuticals Faces Legal Scrutiny Over Allegations of Misleading Investors In a significant development for Rocket Pharmaceuticals, Kuehn Law, PLLC, a law firm specializing in shareholder li…
FDA's New Principles Aim to Revolutionize Rare Disease Therapies The U.S. Food and Drug Administration (FDA) recently unveils the Rare Disease Evidence Principles (RDEP), a groundbreaking initiative d…
Rocket Pharmaceuticals Advances Gene Therapy for Danon Disease Following FDA Approval Rocket Pharmaceuticals Inc. achieves a pivotal milestone as the U.S. Food and Drug Administration (FDA) lifts the…
Rocket Pharmaceuticals Faces Class Action Lawsuit Over Alleged Misleading Claims Rocket Pharmaceuticals, Inc. is currently embroiled in a class action lawsuit that raises significant concerns regardin…
Rocket Pharmaceuticals Faces Legal Action Over Clinical Trial Allegations In a significant development for Rocket Pharmaceuticals, Inc., the company is embroiled in a securities class action lawsuit f…
Legal Scrutiny Intensifies for Rocket Pharmaceuticals Over Alleged Misleading Statements Rocket Pharmaceuticals, Inc. faces significant legal challenges following allegations of misleading statements…
Rocket Pharmaceuticals Reorganizes to Enhance Operational Efficiency and Focus on Gene Therapy Innovations Rocket Pharmaceuticals, Inc., a prominent player in the field of cardiovascular gene therapy,…
Rocket Pharmaceuticals Restructures to Enhance Gene Therapy Development Rocket Pharmaceuticals, Inc. (RCKT) announces a significant corporate reorganization aimed at bolstering its operational capabil…
Rocket Pharmaceuticals Advances Gene Therapy for Danon Disease Rocket Pharmaceuticals Inc. is making strides in the development of its investigational gene therapy, RP-A501, targeting Danon disease, a…
Rocket Pharmaceuticals Advances Gene Therapy for Danon Disease Rocket Pharmaceuticals Inc. (RCKT) is making significant strides in the development of RP-A501, an investigational gene therapy aimed at…
Rocket Pharmaceuticals Advances Gene Therapy for Danon Disease Rocket Pharmaceuticals Inc. (RCKT) is making significant strides in the development of RP-A501, an investigational gene therapy aimed at…
Rocket Pharmaceuticals Enters New Market Segment with RCKT Mortgage Trust In a significant development for Rocket Pharmaceuticals, the company is expanding its reach within the financial sector throug…
Rocket Mortgage Expands Impact in RMBS Market with New Initiative Rocket Mortgage, a prominent player in the residential mortgage sector, takes a significant step forward with the recent announcement…
Rocket Pharmaceuticals Showcases Innovations at J.P. Morgan Healthcare Conference Rocket Pharmaceuticals, Inc., a prominent player in the late-stage biotechnology sector, actively participates in the…
Rocket Pharmaceuticals Showcases Commitment to Genetic Therapies at J.P. Morgan Healthcare Conference Rocket Pharmaceuticals, Inc., a late-stage biotechnology firm specializing in genetic therapies fo…